重组金丝雀痘病毒载体疫苗研制进展

doi:10.19586/j.2095-2341.2021.0046

生物技术进展 ›› 2022, Vol. 12 ›› Issue (1): 36-43.DOI: 10.19586/j.2095-2341.2021.0046

重组金丝雀痘病毒载体疫苗研制进展

李文桂(), 陈雅棠

重庆医科大学附属第一医院传染病寄生虫病研究所，重庆 400016

收稿日期:2021-04-12 接受日期:2021-10-28 出版日期:2022-01-25 发布日期:2022-01-26
通讯作者: 李文桂
作者简介:李文桂 E-mail：cqliwengui@163.com；
基金资助:
国家自然科学基金项目(30801052)

The Status Progress in the Research of Recombinant Vaccine Based on Canarypox Virus

Wengui LI(), Yatang CHEN

Institute of Infectious and Parasitic Diseases，the First Affiliated Hospital，Chongqing Medical University，Chongqing 400016，China

Received:2021-04-12 Accepted:2021-10-28 Online:2022-01-25 Published:2022-01-26
Contact: Wengui LI

摘要/Abstract

摘要：

金丝雀痘病毒（canarypox virus，CNPV）引起的雀痘是一种禽类传染性疾病。CNPV感染后可在宿主体内诱导细胞、体液和黏膜免疫应答，经过改造可开发为一种候选疫苗载体，其可表达病毒和寄生虫的多种蛋白，因此，研制重组CNPV载体疫苗进行免疫预防具有重要的经济意义。国外学者已构建了多种类似疫苗，如马流感病毒（equine influenza virus，EIV）、犬瘟热病毒（canine distemper virus，CDV）、麻疹病毒（measles virus，MV）、尼帕病毒（Nipah virus，NiV）、艾滋病毒（human immunodeficiency virus type 1，HIV?1）、非洲马病病毒4型（African horse sickness virus type 4，AHSV?4）、蓝舌病毒17型（bluetongue virus serotype 17，BTV?17）、丙型肝炎病毒（hepatitis C virus，HCV）、巨细胞病毒（cytomelovirus，CMV）、狂犬病毒（rabies virus）和婴儿利什曼原虫（Leishmania infantum）等。概述了CNPV载体介导的病原体疫苗的构建及其免疫机制等方面的研制现状，旨在为病毒和寄生虫病的免疫预防提供理论依据。

关键词: 金丝雀痘病毒, 疫苗载体, 免疫预防

Abstract:

Poxvirus caused by canarypox virus （CNPV） is an infectious disease of poultry， CNPV infection can induce cellular， humoral and mucosal immune responses in the host. It can be remade as a candidate vaccine vector after modification， which can express multiple proteins of viruses and parasites. Therefore， it is of great economic importance to develop recombinant CNPV vector vaccine for immune prevention. The foreign scholars have constructed a variety of similar vaccines， such as equine influenza virus （EIV）， canine distemper virus （CDV）， measles virus （MV）， Nipah virus （NiV）， human immunodeficiency virus type 1（HIV?1）， African horse sickness virus type 4 （AHSV?4）， bluetongue virus serotype 17 （BTV?17）， hepatitis C virus （HCV）， cytomelovirus （CMV）， rabies virus and Leishmania infantum and so on. This article summerized the status in the research of construction and immune mechanism of CNPV?based vaccines， aiming to provide a theoretical basis for the immune prevention of viruses and parasitic diseases.

Key words: canarypox virus, vaccine vector, immune prevention

中图分类号:

G641

李文桂, 陈雅棠. 重组金丝雀痘病毒载体疫苗研制进展[J]. 生物技术进展, 2022, 12(1): 36-43.

Wengui LI, Yatang CHEN. The Status Progress in the Research of Recombinant Vaccine Based on Canarypox Virus[J]. Current Biotechnology, 2022, 12(1): 36-43.

图/表 1

参考文献 38

1	PLOTKIN S A, CADOZ M, MEIGNIER B, et al.. The Safety and use of canarypox vectored vaccine[J]. Dev. Biol. Stand., 1995, 84(1): 165-170.
2	LUNDSTROM K. Viral vectors in gene therapy[J/OL]. Diseases, 2018, 6: 42[2021-11-26]. .
3	PAILLOT R, RASH N L, GARRETT D, et al.. How to meet the last OIE expert surveillance panel recommendations on equine Influenza (EI) vaccine composition: a review of the process required for the recombinant canarypox-based EI vaccine[J/OL]. Pathogens, 2016, 5: 64[2021-11-26]. .
4	MINKE J M,EL-HAGE C M,TAZAWA P, et al.. Evaluation of the response to an accelerated immunisation schedule using a canarypox-vectored equine influenza vaccine shortened interdose intervals and vaccination of young foals[J]. Aus. Vet. J., 2011, 89(S): 137-139.
5	ADAMS A A, STURGILL T L, BREATHNACH C C, et al.. Humoral and cell-mediated immune responses of old horses following recombinant Canarypox virus vaccination and subsequent challenge infection[J].Vet. Immunol. Immunopathol., 2011, 139(1): 128-140.
6	KARACA K, DUBOVI E J, SIGER L, et al.. Evaluation of the ability of canarypox-vectored equine influenza virus vaccines to induce humoral immune responses against canine influenza viruses in dogs[J]. AJVR, 2007, 68(2): 208-212.
7	STITTELAAR K J, LACOMBE V, LAVIEREN R, et al.. Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine[J]. Vaccine, 2010, 28(36): 4970-4976.
8	COKE R L, BACKUES K A, HOOVER J P, et al.. Serologic responses after vaccination of fennec foxes (Vulpes zerda) and meerkats (Suricata suricatta) with a live, canarypox-vectored canine distemper virus vaccine[J]. J. Zoo Wildl. Med., 2005, 36(2): 326-330.
9	BRONSON E, DEEM S L, SANCHEZ C, et al. Serologic response to a canarypox-vectored Canine distemper virus vaccine in the giant panda (Ailuropoda melanoleuca)[J]. J. Zoo Wildl. Med., 2007, 38(2): 363-366.
10	TAYLOR J, WEINBERG R, TARTAGLIA J, et al.. Nonreplicating viral vectors as potential vaccines:recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins[J]. Virol, 1992, 187(2): 321-328.
11	WEINGARTL H M, BERHANE Y, CASWELL J L, et al.. Recombinant Nipah virus vaccines protect pigs against challenge[J]. J. Virol., 2006, 80(16): 7929-7938.
12	GUILLAUME-VASSELIN V, LEMAITRE L, DHONDT K P, et al.. Protection from Hendra virus infection with canarypox recombinant vaccine[J/OL]. NPJ Vaccines, 2016, 1(20): 16003[2021-11-26]. .
13	COX W, TARTAGLIA J, PAOLETTI E. Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein[J]. Virol, 1993, 195(5): 845-850.
14	LIU J, YU Q G, STONE G W, et al.. CD40L expressed from the canarypox vector,ALVAC,can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8⁺ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals[J]. Vaccine, 2008, 26(18): 4062-4072.
15	Aids Vaccine Evaluation Group022Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with RGP120[J]. J. Infect. Dis., 2001, 183(3): 563-570.
16	PERKS-NGARM S, PITISUTTITHUM P, NITAYAPHAN S, et al.. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand[J]. N. Engl. J. Med., 2009, 361(11): 2209-2220.
17	KIM J H, EXCLER J L, MICHAEL N L. Lessons from the RV144 Thai phase Ⅲ HIV-1 vaccine trial and the search for correlates of protection[J]. Annu. Rev. Med., 2015, 66(2): 423-437.
18	JIN X J, RAMANATHAN J M, BARSOUM S, et al.. Safety and immunogenicity of ALVAC VCP1452 and recombinant GP160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy[J]. J. Virol., 2002, 76(5): 2206-2216.
19	JOHNSON D C, McFARLAND E J, MURESAN P, et al.. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women[J]. J. Infect. Dis., 2005, 192(11): 2129-2133.
20	TEIGLER J E, PHOGAT S, FRANCHINI G, et al.. The canarypox virus vector ALVAC induces distinct cytokine responses compared to the vaccinia virus-based vectors MVA and NYVAC in rhesus monkeys[J]. J. Virol., 2014, 88(3): 1809-1814.
21	POULET H, BRUNET S, BOULARAND C, et al.. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia[J].Vet. Rec., 2003, 153(1): 141-145.
22	GROSENBAUGH D A, LEARD T, PARDO C. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine[J]. J. Am. Vet. Med. Assoc., 2006, 228(4): 726-727.
23	SCHLECHT-LOUF G, MANGENEY M, EL-GARCH H, et al.. A targeted mutation within the Feline leukemia virus(FeLV) envelope protein immunosuppressive domain to improve a canarypox virus-vectored FeLV vaccine[J]. J. Virol., 2014, 88(5): 992-1001.
24	PATEL M, CARRITT K, LANE J, et al.. Comparative efficacy of Feline leukemia virus(FeLV) inactivated whole-virus vaccine and canarypox virus-vectored vaccine during virulent FeLV challenge and immunosuppression[J]. Clin. Vac. Immunol., 2015, 22(7): 798-805.
25	GUTHRIE A J, QUAN M, LOURENS C W, et al.. Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus[J]. Vaccine, 2009, 27(25): 4434-4438.
26	GARCH H E, CRAFFORD J E E, AMOUYAL P, et al.. An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses[J].Vet. Immunol. Immunopathol., 2012, 149(1): 76-85.
27	ZANETTI F A, GRAND M D C, MITAROTONDA R C, et al.. Canarypox virus expressing infectious bursal disease VP2 protein as immunogen for chickens[J]. Braz. J. Microbiol., 2014, 45(7): 1231-1234.
28	BOONE J D, BALASURIYA U B, KARACA K, et al.. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep[J]. Vaccine, 2007, 25(4): 672-678.
29	KARACA K, BOWEN R, AUSTGEN L E, et al.. Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge[J]. Vaccine, 2005, 23(23): 3808-3813.
30	MINKE J M, SIGER L, CUPILLARD L, et al.. Protection provided by a recombinant ALVAC-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain[J]. Vaccine, 2011, 29(27): 4608-4612.
31	PANCHOLI P, LIU Q Y, TRICOCHE N, et al.. DNA prime-canarypox boost with polycistronic Hepatitis C virus(HCV) genes generates potent immune responses to HCV structural and nonstructural proteins[J]. J. Infect. Dis., 2000, 182(1): 18-27.
32	PANCHOLI P,PERKUS M, TRICOCHE N, et al.. DNA immunization with Hepatitis C virus(HCV) polycistronic genes or immunization by HCV DNA priming-recombinant canarypox virus boosting induces immune responses and protection from recombinant HCV-Vaccinia virus infection in HLA-A2.1-transgenic mice[J]. J. Virol., 2003, 77(1): 382-390.
33	BERNSTEIN D I, SCHLEISS M R, BERENCSI K, et al.. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus(CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults[J]. J. Infect. Dis., 2002, 18(S): 486-490.
34	MINKE J M, FISCHER L, BAUDU P H, et al.. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine Herpes virus vaccination[J].Vet. Immunol. Immunopathol., 2006, 111(1): 47-57.
35	JAS D, COUPIER C, TOULERMONDE C E, et al.. Three-year duration of immunity in cats vaccinated with a canarypox-vectored recombinant Rabies virus vaccine[J]. Vaccine, 2012, 30(49): 6991-6996.
36	MARROW J C, PADILLA L R, HAYEK L A C, et al.. Comparison of antibody response to a non-adjuvanted live canarypox-vectored recombinant rabies vaccine and a killed adjuvanted rabies vaccine in Eld's deer(rucervus eldithamin)[J]. J. Zoo Wildl. Med., 2014, 45(2): 315-320.
37	FISCHER L, LE GROS F X, MASON P W, et al.. A recombinant canarypox virus protects rabbits against a lethal Rabbit hemorrhagic disease virus (RHDV) challenge[J]. Vaccine, 1997, 15(1): 90-96.
38	ABBEHUSEN M M C, CUNHA J, SUAREZ M S, et al. Immunization of experimental dogs with salivary proteins from Lutzomyia longipalpis,using DNA and recombinant canarypox virus induces immune responses consistent with protection against leishmania infantum[J/OL]. Front. Immunol., 2019, 10: 1828[2021-11-26]. .

病原体	病原体	目的基因	载体	接种宿主	免疫应答的类型	保护力诱导	临床研究阶段	参考文献
正粘病毒	马流感病毒	HA	pALVAC	儿马、成年马	体液免疫	能	动物试验	[3⁃6]
正粘病毒	禽流感病毒	HA	—	幼猫	体液免疫	能	动物试验	[7]
副粘病毒	犬瘟热病毒	糖蛋白H	—	狐狸、大熊猫	体液免疫	—	动物试验	[89]
	麻疹病毒	F/HA	pSPMF	毕格犬	体液免疫	能	动物试验	[10]
	尼帕病毒	F	pALVAC	仔猪	体液免疫	能	动物试验	[11]
	亨得拉病毒	G/F	pALVAC	仓鼠	体液免疫	能	动物试验	[12]
逆转录病毒	HIV‑1	env	—	小鼠、健康志愿者、AIDS患者	细胞和体液免疫	—	Ⅰ、Ⅱ和Ⅲ期临床试验	[1319]
	SIV	env	—	恒河猴	细胞免疫	—	动物试验	[20]
	猫白血病病毒	env	PALVAC和pDFG	仔猫和仔猪	体液免疫	能	动物试验	[21⁃24]
双链RNA病毒	非洲马病病毒4型	VP2/VP5	pALVAC	Boerperd马	体液免疫	能	动物试验	[2526]
	传染性法氏囊病病毒	VP2	pALVAC	莱杭鸡	体液免疫	—	动物试验	[27]
	蓝舌病毒17型	VP2/VP5	pALVAC	绵羊	体液免疫	能	动物试验	[28]
黄病毒	西尼罗病毒	PrM/E	—	猫、狗、儿马、矮种马	细胞和体液免疫	能	动物试验	[2930]
黄病毒	丙型肝炎病毒	NS3	PRC	小鼠	细胞免疫	能	动物试验	[3132]
疱疹病毒	巨细胞病毒	gB	—	健康志愿者	细胞和体液免疫	—	Ⅰ期临床试验	[33]
疱疹病毒	马疱疹病毒1型	gB	pALVAC	矮种马	体液免疫	能	动物试验	[34]
其他	狂犬病毒	RGP	—	小鼠、犬、猫、健康志愿者	体液免疫		Ⅰ期临床试验	[3536]
	兔出血热病毒	cap	pALVAC	兔	体液免疫	—	动物试验	[37]
	婴儿利什曼原虫	LJM17	—	毕格犬	体液免疫	能	动物试验	[38]

病原体	病原体	目的基因	载体	接种宿主	免疫应答的类型	保护力诱导	临床研究阶段	参考文献
正粘病毒	马流感病毒	HA	pALVAC	儿马、成年马	体液免疫	能	动物试验	[3⁃6]
正粘病毒	禽流感病毒	HA	—	幼猫	体液免疫	能	动物试验	[7]
副粘病毒	犬瘟热病毒	糖蛋白H	—	狐狸、大熊猫	体液免疫	—	动物试验	[89]
	麻疹病毒	F/HA	pSPMF	毕格犬	体液免疫	能	动物试验	[10]
	尼帕病毒	F	pALVAC	仔猪	体液免疫	能	动物试验	[11]
	亨得拉病毒	G/F	pALVAC	仓鼠	体液免疫	能	动物试验	[12]
逆转录病毒	HIV‑1	env	—	小鼠、健康志愿者、AIDS患者	细胞和体液免疫	—	Ⅰ、Ⅱ和Ⅲ期临床试验	[1319]
	SIV	env	—	恒河猴	细胞免疫	—	动物试验	[20]
	猫白血病病毒	env	PALVAC和pDFG	仔猫和仔猪	体液免疫	能	动物试验	[21⁃24]
双链RNA病毒	非洲马病病毒4型	VP2/VP5	pALVAC	Boerperd马	体液免疫	能	动物试验	[2526]
	传染性法氏囊病病毒	VP2	pALVAC	莱杭鸡	体液免疫	—	动物试验	[27]
	蓝舌病毒17型	VP2/VP5	pALVAC	绵羊	体液免疫	能	动物试验	[28]
黄病毒	西尼罗病毒	PrM/E	—	猫、狗、儿马、矮种马	细胞和体液免疫	能	动物试验	[2930]
黄病毒	丙型肝炎病毒	NS3	PRC	小鼠	细胞免疫	能	动物试验	[3132]
疱疹病毒	巨细胞病毒	gB	—	健康志愿者	细胞和体液免疫	—	Ⅰ期临床试验	[33]
疱疹病毒	马疱疹病毒1型	gB	pALVAC	矮种马	体液免疫	能	动物试验	[34]
其他	狂犬病毒	RGP	—	小鼠、犬、猫、健康志愿者	体液免疫		Ⅰ期临床试验	[3536]
	兔出血热病毒	cap	pALVAC	兔	体液免疫	—	动物试验	[37]
	婴儿利什曼原虫	LJM17	—	毕格犬	体液免疫	能	动物试验	[38]

重组金丝雀痘病毒载体疫苗研制进展

The Status Progress in the Research of Recombinant Vaccine Based on Canarypox Virus

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 38

相关文章 0

编辑推荐

Metrics

本文评价